The variant rs2232228 in the HAS3 gene, which is believed to reduce the ability of HAS3 to synthesize hyaluronan, was identified to be associated with an ~9-fold increased risk of developing AIC in a cohort of pediatric cancer survivors [73]. The gene discussed is HAS3; the disease is cancer.